DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed advanced solid tumors, including brain tumors and lymphomas, that have failed standard therapy (surgery, radiotherapy, endocrine therapy, or chemotherapy) or for which no standard therapy exists
• * Histology requirement waived for brain stem gliomas
• PATIENT CHARACTERISTICS:
• Age:
• 21 and under at diagnosis
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 8 weeks
• Hematopoietic:
• Absolute neutrophil count at least 750/mm\^3
• Platelet count at least 75,000/mm\^3
• Hemoglobin at least 8.5 g/dL
• Hepatic:
• Bilirubin no greater than 1.5 mg/dL
• SGOT or SGPT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases)
• Renal:
• Creatinine no greater than 1.5 times ULN OR
• GFR at least 70 mL/min
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• No history of severe or life-threatening hypersensitivity to camptothecin analogs
• HIV negative
• No other concurrent severe or uncontrolled medical illness
• No systemic infection
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Recovered from prior immunotherapy
• Chemotherapy:
• See Disease Characteristics
• Recovered from prior chemotherapy
• Endocrine therapy:
• See Disease Characteristics
• Radiotherapy:
• See Disease Characteristics
• At least 4 weeks since prior extensive radiotherapy involving cranial, whole pelvic, or at least 25% of bone marrow reserve
• Recovered from prior radiotherapy
• Concurrent localized radiotherapy for pain allowed
• Surgery:
• See Disease Characteristics
• Recovered from prior surgery
• Other:
• No other concurrent antitumor therapy
• No concurrent drugs that induce or inhibit CYP3A enzyme